JAMES GARVIN: Open Payments
NPI 1447641352 · AZLE, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$384 in 18 payments from 12 companies in 2025. Trend: 2023 $157 · 2024 $862 · 2025 $384
Food & beverage: $384
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 3 | $77 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $54 |
| AstraZeneca Pharmaceuticals LP | 3 | $54 |
| Phathom Pharmaceuticals, Inc. | 2 | $37 |
| PFIZER INC. | 1 | $29 |
| BioCryst US Sales Co., LLC | 1 | $27 |
| Smith+Nephew, Inc. | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Lilly USA, LLC | 1 | $18 |
| Phadia US Inc. | 1 | $16 |
Products named: DUPIXENT, NEFFY, VOQUEZNA, AIRSUPRA, OCTAGAM IMMUNE GLOBULIN (HUMAN), ORLADEYO, Versajet, FASENRA.
Industry payments across TX — which companies pay providers there.
